This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Beyza Bulutoglu, PhD
Principal Scientist, Large Molecule Drug Discovery at Genentech

Profile

Dr. Bulutoglu pursued her master’s studies in Biomedical Engineering at Yale University followed by Ph.D. studies in Chemical Engineering at Columbia University. Following her postdoctoral appointment at the Center for Engineering in Medicine & Surgery, in affiliation with Harvard Medical School and Massachusetts General Hospital, she joined the Protein Chemistry Department within the Large Molecule Drug Discovery Organization at Genentech as a Principal Scientist.

Her graduate work focused on application-oriented protein engineering, where she engineered various domains, including enzymes and stimulus-responsive peptides, to serve as building blocks in biotechnology applications. She was awarded the NIH Ruth L. Kirschstein Fellowship during her postdoc and conducted studies in the areas of synthetic biology, genetic engineering, tissue and cellular engineering. At Genentech, she leads a protein engineering group focusing on the design and application of different modalities to discover and develop new therapies for patients.

Agenda Sessions

  • Engineered IL-18 Variants with Half-life Extension and Improved Stability for Cancer Immunotherapy

    11:20